These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 9260730)

  • 1. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.
    Rabey JM; Bass H; Bonuccelli U; Brooks D; Klotz P; Korczyn AD; Kraus P; Martinez-Martin P; Morrish P; Van Sauten W; Van Hilten B
    Clin Neuropharmacol; 1997 Aug; 20(4):322-37. PubMed ID: 9260730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric properties of the Unified Parkinson's Disease Rating Scale and of the Short Parkinson's Evaluation Scale.
    Martignoni E; Franchignoni F; Pasetti C; Ferriero G; Picco D
    Neurol Sci; 2003 Oct; 24(3):190-1. PubMed ID: 14598081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
    van Hilten JJ; van der Zwan AD; Zwinderman AH; Roos RA
    Mov Disord; 1994 Jan; 9(1):84-8. PubMed ID: 8139609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
    Siderowf A; McDermott M; Kieburtz K; Blindauer K; Plumb S; Shoulson I;
    Mov Disord; 2002 Jul; 17(4):758-63. PubMed ID: 12210871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination.
    Richards M; Marder K; Cote L; Mayeux R
    Mov Disord; 1994 Jan; 9(1):89-91. PubMed ID: 8139610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.
    Martínez-Martín P; Gil-Nagel A; Gracia LM; Gómez JB; Martínez-Sarriés J; Bermejo F
    Mov Disord; 1994 Jan; 9(1):76-83. PubMed ID: 8139608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness of impairments and disabilities in Parkinson's disease.
    Visser M; Marinus J; Stiggelbout AM; van Hilten JJ
    Parkinsonism Relat Disord; 2006 Jun; 12(5):314-8. PubMed ID: 16621658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
    Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teaching tape for the motor section of the unified Parkinson's disease rating scale.
    Goetz CG; Stebbins GT; Chmura TA; Fahn S; Klawans HL; Marsden CD
    Mov Disord; 1995 May; 10(3):263-6. PubMed ID: 7544438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section.
    Stebbins GT; Goetz CG
    Mov Disord; 1998 Jul; 13(4):633-6. PubMed ID: 9686766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease.
    Ramaker C; Marinus J; Stiggelbout AM; Van Hilten BJ
    Mov Disord; 2002 Sep; 17(5):867-76. PubMed ID: 12360535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal clinically important change on the unified Parkinson's disease rating scale.
    Schrag A; Sampaio C; Counsell N; Poewe W
    Mov Disord; 2006 Aug; 21(8):1200-7. PubMed ID: 16673410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinically important difference on the unified Parkinson's disease rating scale.
    Shulman LM; Gruber-Baldini AL; Anderson KE; Fishman PS; Reich SG; Weiner WJ
    Arch Neurol; 2010 Jan; 67(1):64-70. PubMed ID: 20065131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metric attributes of the unified Parkinson's disease rating scale 3.0 battery: Part I, feasibility, scaling assumptions, reliability, and precision.
    Martinez-Martin P; Forjaz MJ
    Mov Disord; 2006 Aug; 21(8):1182-8. PubMed ID: 16673397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postural instability in idiopathic Parkinson's disease: discriminating fallers from nonfallers based on standardized clinical measures.
    Landers MR; Backlund A; Davenport J; Fortune J; Schuerman S; Altenburger P
    J Neurol Phys Ther; 2008 Jun; 32(2):56-61. PubMed ID: 18645292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
    Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
    Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the motor complications of Parkinson's disease on the quality of life.
    Chapuis S; Ouchchane L; Metz O; Gerbaud L; Durif F
    Mov Disord; 2005 Feb; 20(2):224-30. PubMed ID: 15384126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.